Clinical Trial: Citrulline Allo. Evaluation of Citrullinemia as a Marker of Bowel Damage After Allogeneic Bone Marrow Transplantation in Children

Study Status: Completed
Recruit Status: Unknown status
Study Type: Observational

Official Title: Evaluation of Citrullinemia as a Marker of Bowel Damage After Allogeneic Bone Marrow Transplantation in Children

Brief Summary: determine the interest of the dosage of citrullinemia to monitor the bowel damage after allogeneic bone marrow transplantation in children.

Detailed Summary:

30 children included. Dosage of citrullinemia on day -7, day 0 and every week up to 100 days after BMT. Histological examination and extensive infectious screening in case of persistent digestive symptoms (more than 3 days).

Two groups of patients regarding on digestive involvement. Comparison of the values of citrullinemia between these two groups.

Sponsor: University Hospital, Clermont-Ferrand

Current Primary Outcome: Citrullinemia (weekly) [ Time Frame: weekly ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Gastro-intestinal complications in children following allogeneic bone marrow transplantation [ Time Frame: following allogenic bone marrow transplantation ]

Original Secondary Outcome: Same as current

Information By: University Hospital, Clermont-Ferrand

Dates:
Date Received: September 9, 2008
Date Started: April 2008
Date Completion: September 2009
Last Updated: January 18, 2011
Last Verified: January 2011